Clinical Trials Logo

Myalgia clinical trials

View clinical trials related to Myalgia.

Filter by:

NCT ID: NCT02746250 Completed - Clinical trials for Tension-type Headache

Muscle Soreness and Stiffness in Patients With Chronic or Frequent Episodic Tension Type Headache.

Start date: March 2016
Phase: N/A
Study type: Interventional

The aim is to investigate muscle soreness and stiffness in patients with Chronic or Frequent Episodic Tension Type Headache before and after treatment with amitriptyline - and to compare the results with healthy individuals.

NCT ID: NCT02695381 Completed - Clinical trials for Acute Delayed Onset Muscle Soreness (DOMS)

Etodolac-lidocaine Patch in Subjects Experiencing Acute Delayed Onset Muscle Soreness

Start date: March 2016
Phase: Phase 3
Study type: Interventional

This study evaluate the efficacy and safety of Etodolac-lidocaine topical patch applied one time daily when compared with placebo in the treatment of acute Delayed Onset Muscle Soreness (DOMS) of the upper limbs.

NCT ID: NCT02693678 Completed - Clinical trials for Musculoskeletal Pain

Real and Sham Diathermy vs Hand Massage in Lower Limbs Delayed Onset Muscle Soreness (DOMS)Effect on Knee Proprioception

Start date: April 2016
Phase: N/A
Study type: Interventional

Delayed onset muscle soreness (DOMS) can have an impact on the proprioception of knee joint . The study aim is to assess the effect of manual massage, diathermy and sham diathermy the proprioception of the knee joint in patients affected by DOMS.

NCT ID: NCT02685202 Terminated - Myalgia Clinical Trials

Temporomandibular Disorder (TMD) Pain in Response to Jaw Advancement in People With TMD and Obstructive Sleep Apnea

Start date: March 2016
Phase: N/A
Study type: Interventional

The purpose of this study is to characterize the course of temporomandibular disorder (TMD) pain in adults with TMD and obstructive sleep apnea (OSA), all of whom are being treated with mandibular advancement splint (MAS) therapy. Study participants are 12 adults with painful TMD and comorbid mild to moderate OSA (apnea-hypopnea index ≥5 and <30). This is an interventional study in which 12 patients receive MAS therapy for comorbid TMD/OSA for 16 weeks. It is standard of care to treat mild or moderate OSA with MAS therapy, the the effect on MAS therapy on TMD pain in people with OSA is unknown. There is no comparison group. Care is being provided under the direction of a sleep physician by a dentist who specializes in dental sleep medicine. The investigators expect that as MAS therapy reduces the severity of OSA, painful TMD symptoms will also reduce.

NCT ID: NCT02602353 Completed - Clinical trials for Delayed Onset Muscle Soreness

Pilot Study Comparing the Efficacy and Safety of a New Pain Patch and Placebo in Delayed Onset Muscle Soreness (DOMS)

Start date: October 2015
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the analgesic efficacy and safety of a new pain patch compared to placebo and no treatment in subjects experiencing Delayed Onset Muscle Soreness (DOMS).

NCT ID: NCT02597634 Completed - Clinical trials for Delayed Onset Muscle Soreness, DOMS

Study of SST-0225 Topical Ibuprofen Cream in the Treatment of Delayed Onset Muscle Soreness (DOMS)

DOMS
Start date: November 2015
Phase: Phase 3
Study type: Interventional

This is a Phase 3, prospective, randomized, dual-center, double-blind, placebo-controlled, parallel-group study designed to determine the efficacy and safety of SST-0225 (5.4 grams, applied up to 6 times in 24 hours, over a 48-hour dosing period) for the treatment of pain associated with DOMS.

NCT ID: NCT02548208 Completed - Clinical trials for Musculoskeletal Pain

Single Focused Shock Wave in the Release od Delayed Onset Muscle Soreness (DOMS)

Start date: January 2011
Phase: N/A
Study type: Interventional

The study is a single-center, double blinded, randomized controlled trial aimed to investigate the effects of focused extracorporeal shockwave therapy (fESWT) on Delayed Onset Muscle Soreness (DOMS) of the non-dominant biceps brachialis muscle in healthy voluntary adults.

NCT ID: NCT02519387 Completed - Clinical trials for Rheumatoid Arthritis

Efficacy and Safety of Buprenorphine Transdermal Patch in Non-cancer Pain of Moderate Intensity

Start date: July 2013
Phase: Phase 4
Study type: Interventional

This is a phase IV, open-label and single-arm study of patients with non-malignant pain due to osteoarthritis, rheumatoid arthritis, low back pain and joint/muscle pain, who were not responding to non-opioid analgesics. The primary objective was to assess the efficacy of buprenorphine transdermal patch for pain control among these patients.

NCT ID: NCT02481193 Completed - Fasciculation Clinical Trials

Effects of Cisatracurium on Succinylcholine-induced Fasciculations and Myalgia

Start date: March 2013
Phase: Phase 3
Study type: Interventional

The purpose of this study is to investigate the effects of different doses of cisatracurium pretreatment on succinylcholine-induced fasciculations and postoperative myalgia.

NCT ID: NCT02444091 Completed - Clinical trials for Chronic Fatigue Syndrome (CFS)

Cyclophosphamide in Myalgic Encephalopathy/ Chronic Fatigue Syndrome (ME/CFS)

CycloME
Start date: March 2015
Phase: Phase 2
Study type: Interventional

Significant clinical improvements of ME/CFS symptoms were observed in two patients with long-standing ME/CFS who received adjuvant chemotherapy including cyclophosphamide for breast cancer, also in one ME/CFS patient who received chemotherapy including iphosphamide for Hodgkin lymphoma. Three pilot ME/CFS patients were thereafter treated with six intravenous infusions four weeks apart, in two of these with a significant clinical response. The hypothesis is that a subset of ME/CFS patients have an activated immune system, and that ME/CFS symptoms may be alleviated by treatment with cyclophosphamide as intravenous pulse infusions four weeks apart, six infusions in total. The purpose of the present study is to treat ME/CFS patients with cyclophosphamide as intravenous pulse infusions four weeks apart, six infusions in total. The effects on ME/CFS symptoms and tolerability/side effects during 12 months follow-up will be registered, and additional tests will be performed to objectively register changes in physical ability during follow-up. Studies to investigate possible large vessel endothelial dysfunction and skin microvascular dysfunction will be performed before start of intervention and during follow-up.